A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90
Last updated 2026-01-08
Summary
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
Conditions
- Lymphoma, Follicular
Interventions
- DRUG
-
Golcadomide
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Doxorubicin
Specified dose on specified days
- DRUG
-
Vincristine
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
Sponsors & Collaborators
-
Celgene
lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-08-30
- Primary Completion
- 2026-11-23
- Completion
- 2028-11-27
- FDA Drug
- Yes
Countries
- United States
- Australia
- Brazil
- Canada
- Chile
- France
- Germany
- Italy
- Poland
- South Korea
- Spain
- Taiwan
- United Kingdom
Study Locations
More Related Trials
-
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
NCT00392834 ·Status: COMPLETED ·Phase: PHASE2
-
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
NCT01216683 ·Status: COMPLETED ·Phase: PHASE2
-
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
NCT02031419 ·Status: TERMINATED ·Phase: PHASE1
-
Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma
NCT00242996 ·Status: COMPLETED ·Phase: PHASE2
-
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
NCT06209619 ·Status: RECRUITING ·Phase: PHASE1
-
Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma
NCT01130194 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
NCT01650701 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04285268 ·Status: WITHDRAWN ·Phase: PHASE2
-
Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma
NCT00509379 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
NCT00295932 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01412879 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
NCT01829568 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study
NCT04842318 ·Status: UNKNOWN ·Phase: PHASE4
-
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma
NCT00169208 ·Status: COMPLETED ·Phase: PHASE2
-
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
NCT00543114 ·Status: TERMINATED ·Phase: PHASE1
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
NCT01729104 ·Status: TERMINATED ·Phase: PHASE1
-
Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma
NCT00227695 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
NCT00301795 ·Status: TERMINATED ·Phase: PHASE2
-
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
NCT00562965 ·Status: TERMINATED ·Phase: PHASE3
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
NCT00003204 ·Status: COMPLETED ·Phase: PHASE3
-
Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma
NCT01523860 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma
NCT00689845 ·Status: UNKNOWN ·Phase: NA
-
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
NCT01232556 ·Status: TERMINATED ·Phase: PHASE3
-
Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma
NCT01939730 ·Status: COMPLETED ·Phase: PHASE2